PTIX — Protagenic Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $6.30m
- $6.22m
Annual balance sheet for Protagenic Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 8-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10.4 | 7.98 | 4.06 | 1.84 | 0.015 |
| Net Total Receivables | — | — | — | — | 0.074 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 11.1 | 8.04 | 4.2 | 1.88 | 0.089 |
| Net Property, Plant And Equipment | — | 0.002 | 0.123 | 0.073 | — |
| Total Assets | 11.1 | 8.04 | 4.32 | 1.96 | 0.089 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.8 | 1.12 | 0.655 | 0.943 | 5.04 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.12 | 1.12 | 0.655 | 0.943 | 5.04 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 9.94 | 6.92 | 3.67 | 1.01 | -4.95 |
| Total Liabilities & Shareholders' Equity | 11.1 | 8.04 | 4.32 | 1.96 | 0.089 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |